

Paolo Fusar-Poli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8896038/publications.pdf>

Version: 2024-02-01

493
papers

37,196
citations

2544

96
h-index

4548

171
g-index

518
all docs

518
docs citations

518
times ranked

26460
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of COVID-19 lockdown on child and adolescent mental health: systematic review. <i>European Child and Adolescent Psychiatry</i> , 2023, 32, 1151-1177.	4.7	364
2	Impact of data extraction errors in meta-analyses on the association between depression and peripheral inflammatory biomarkers: an umbrella review. <i>Psychological Medicine</i> , 2023, 53, 2017-2030.	4.5	4
3	Establishing a business case for setting up early detection services for preventing psychosis. <i>BJPsych Bulletin</i> , 2023, 47, 156-165.	1.1	2
4	Psychosis and substance abuse increase the COVID-19 mortality risk. <i>Psychological Medicine</i> , 2023, 53, 4236-4244.	4.5	7
5	Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2023, 62, 151-168.	0.5	22
6	Antipsychotics and Attenuated Psychosis Syndrome: Transdiagnostic assessment and discontinuation strategies. <i>Schizophrenia Research</i> , 2022, 243, 402-404.	2.0	2
7	Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. <i>Molecular Psychiatry</i> , 2022, 27, 281-295.	7.9	967
8	The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic. <i>Journal of Affective Disorders</i> , 2022, 299, 393-407.	4.1	22
9	Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis. <i>Schizophrenia Bulletin</i> , 2022, 48, 100-110.	4.3	9
10	Structural Brain Volumes of Individuals at Clinical High Risk for Psychosis: A Meta-analysis. <i>Biological Psychiatry Global Open Science</i> , 2022, 2, 147-152.	2.2	10
11	Development of a probability calculator for psychosis risk in children, adolescents, and young adults. <i>Psychological Medicine</i> , 2022, 52, 3159-3167.	4.5	9
12	Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). <i>Journal of Affective Disorders</i> , 2022, 299, 367-376.	4.1	33
13	Promoting good mental health in the whole population: The new frontier. <i>European Neuropsychopharmacology</i> , 2022, 55, 8-10.	0.7	9
14	Diagnosis, prognosis, and treatment of brief psychotic episodes: a review and research agenda. <i>Lancet Psychiatry</i> , 2022, 9, 72-83.	7.4	24
15	A large-scale meta-analytic atlas of mental health problems prevalence during the COVID-19 early pandemic. <i>Journal of Medical Virology</i> , 2022, 94, 1935-1949.	5.0	134
16	Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review. <i>European Neuropsychopharmacology</i> , 2022, 55, 112-157.	0.7	7
17	Public health primary prevention implemented by clinical high-risk services for psychosis. <i>Translational Psychiatry</i> , 2022, 12, 43.	4.8	14
18	Clinical outcomes in individuals at clinical high risk of psychosis who do not transition to psychosis: a meta-analysis. <i>Epidemiology and Psychiatric Sciences</i> , 2022, 31, e9.	3.9	26

#	ARTICLE	IF	CITATIONS
19	Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials. <i>JAMA Psychiatry</i> , 2022, 79, 210.	11.0	47
20	Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe. <i>Neuropsychiatric Disease and Treatment</i> , 2022, Volume 18, 201-219.	2.2	3
21	Understanding source monitoring subtypes and their relation to psychosis: a systematic review and meta-analysis. <i>Psychiatry and Clinical Neurosciences</i> , 2022, 76, 162-171.	1.8	14
22	Association between autism spectrum disorder and inflammatory bowel disease: A systematic review and meta-analysis. <i>Autism Research</i> , 2022, 15, 340-352.	3.8	19
23	A systematic review and meta-analysis of structural and functional brain alterations in individuals with genetic and clinical high-risk for psychosis and bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 117, 110540.	4.8	20
24	Development of the Korea-Polyenvironmental Risk Score for Psychosis. <i>Psychiatry Investigation</i> , 2022, 19, 197-206.	1.6	5
25	Differential expression of MicroRNAs in Alzheimer's disease: a systematic review and meta-analysis. <i>Molecular Psychiatry</i> , 2022, 27, 2405-2413.	7.9	21
26	Relapse prevention in schizophrenia. <i>Lancet Psychiatry</i> , 2022, 9, e13.	7.4	1
27	Clinical prediction models in psychiatry: a systematic review of two decades of progress and challenges. <i>Molecular Psychiatry</i> , 2022, 27, 2700-2708.	7.9	49
28	Higher levels of mental wellbeing predict lower risk of common mental disorders in the Danish general population. <i>Mental Health and Prevention</i> , 2022, 26, 200233.	1.3	9
29	Identifying Electroencephalography Biomarkers in Individuals at Clinical High Risk for Psychosis in an International Multi-Site Study. <i>Frontiers in Psychiatry</i> , 2022, 13, 828376.	2.6	1
30	Perceived Family Functioning Profile in Adolescents at Clinical High Risk for Psychosis: Rigidity as a Possible Preventive Target. <i>Frontiers in Psychiatry</i> , 2022, 13, 861201.	2.6	1
31	Associations between mental and physical conditions in children and adolescents: An umbrella review. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 137, 104662.	6.1	30
32	Global population attributable fraction of potentially modifiable risk factors for mental disorders: a meta-umbrella systematic review. <i>Molecular Psychiatry</i> , 2022, 27, 3510-3519.	7.9	29
33	The lived experience of psychosis: a bottom-up review co-written by experts by experience and academics. <i>World Psychiatry</i> , 2022, 21, 168-188.	10.4	67
34	Associating Violence With Schizophrenia's Risks and Biases. <i>JAMA Psychiatry</i> , 2022, 79, 738.	11.0	2
35	Examining the variability of neurocognitive functioning in individuals at clinical high risk for psychosis: a meta-analysis. <i>Translational Psychiatry</i> , 2022, 12, 198.	4.8	7
36	Associations of presenting symptoms and subsequent adverse clinical outcomes in people with unipolar depression: a prospective natural language processing (NLP), transdiagnostic, network analysis of electronic health record (EHR) data. <i>BMJ Open</i> , 2022, 12, e056541.	1.9	1

#	ARTICLE	IF	CITATIONS
37	Prognostic accuracy and clinical utility of psychometric instruments for individuals at clinical high-risk of psychosis: a systematic review and meta-analysis. <i>Molecular Psychiatry</i> , 2022, 27, 3670-3678.	7.9	13
38	Incidence, prevalence, and global burden of autism spectrum disorder from 1990 to 2019 across 204 countries. <i>Molecular Psychiatry</i> , 2022, 27, 4172-4180.	7.9	52
39	Clinical high at-risk mental state in young subjects accessing a mental disorder prevention service in Italy. <i>Psychiatry Research</i> , 2022, 316, 114710.	3.3	1
40	Real-World Implementation of Precision Psychiatry: A Systematic Review of Barriers and Facilitators. <i>Brain Sciences</i> , 2022, 12, 934.	2.3	10
41	Environmental risk factors, protective factors, and biomarkers for postpartum depressive symptoms: an umbrella review. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 140, 104761.	6.1	5
42	The gut-microbiome as a target for the treatment of schizophrenia: A systematic review and meta-analysis of randomised controlled trials of add-on strategies. <i>Schizophrenia Research</i> , 2021, 234, 58-70.	2.0	33
43	Evaluation of variability in individual response to treatments in the clinical high-risk state for psychosis: A meta-analysis. <i>Schizophrenia Research</i> , 2021, 227, 20-27.	2.0	11
44	Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit. <i>Schizophrenia Research</i> , 2021, 227, 10-17.	2.0	28
45	Real-world implementation of precision psychiatry: Transdiagnostic risk calculator for the automatic detection of individuals at-risk of psychosis. <i>Schizophrenia Research</i> , 2021, 227, 52-60.	2.0	30
46	Examining service user perspectives for the development of a good outcome checklist for individuals at clinical high risk for psychosis. <i>Microbial Biotechnology</i> , 2021, 15, 606-615.	1.7	5
47	Using Natural Language Processing on Electronic Health Records to Enhance Detection and Prediction of Psychosis Risk. <i>Schizophrenia Bulletin</i> , 2021, 47, 405-414.	4.3	36
48	Lower speech connectedness linked to incidence of psychosis in people at clinical high risk. <i>Schizophrenia Research</i> , 2021, 228, 493-501.	2.0	40
49	The prevalence, odds and predictors of lifespan comorbid eating disorder among people with a primary diagnosis of bipolar disorders, and vice-versa: Systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2021, 280, 409-431.	4.1	28
50	The case for improved transdiagnostic detection of first-episode psychosis: Electronic health record cohort study. <i>Schizophrenia Research</i> , 2021, 228, 547-554.	2.0	3
51	Risk and protective factors for alcohol and tobacco related disorders: An umbrella review of observational studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 121, 20-28.	6.1	6
52	Annual Research Review: Prevention of psychosis in adolescents – systematic review and meta-analysis of advances in detection, prognosis and intervention. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2021, 62, 657-673.	5.2	95
53	Implementing Precision Psychiatry: A Systematic Review of Individualized Prediction Models for Clinical Practice. <i>Schizophrenia Bulletin</i> , 2021, 47, 284-297.	4.3	101
54	Psychotic experiences, psychiatric comorbidity and mental health need in the general population: a cross-sectional and cohort study in Southeast London. <i>Psychological Medicine</i> , 2021, 51, 147-157.	4.5	17

#	ARTICLE	IF	CITATIONS
55	Can we increase the subjective well-being of the general population? An umbrella review of the evidence. <i>Revista De Psiquiatria Y Salud Mental</i> , 2021, 14, 50-64.	1.8	6
56	Risk and protective factors for mental disorders with onset in childhood/adolescence: An umbrella review of published meta-analyses of observational longitudinal studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 120, 565-573.	6.1	14
57	Suicide, self-harm and thoughts of suicide or self-harm in infectious disease epidemics: a systematic review and meta-analysis. <i>Epidemiology and Psychiatric Sciences</i> , 2021, 30, e32.	3.9	35
58	Can we increase the subjective well-being of the general population? An umbrella review of the evidence. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2021, 14, 50-64.	0.3	1
59	Transition to psychosis in randomized clinical trials of individuals at clinical high risk of psychosis compared to observational cohorts: a systematic review and meta-analysis. <i>European Psychiatry</i> , 2021, 64, e51.	0.2	7
60	Suicide, self-harm and thoughts of suicide or self-harm in infectious disease epidemics: a systematic review and meta-analysis – CORRIGENDUM. <i>Epidemiology and Psychiatric Sciences</i> , 2021, 30, .	3.9	7
61	Third external replication of an individualised transdiagnostic prediction model for the automatic detection of individuals at risk of psychosis using electronic health records. <i>Schizophrenia Research</i> , 2021, 228, 403-409.	2.0	10
62	Gender differences in clinical presentation and illicit substance use during first episode psychosis: a natural language processing, electronic case register study. <i>BMJ Open</i> , 2021, 11, e042949.	1.9	20
63	Universal and Selective Interventions to Prevent Poor Mental Health Outcomes in Young People: Systematic Review and Meta-analysis. <i>Harvard Review of Psychiatry</i> , 2021, 29, 196-215.	2.1	28
64	Preventive psychiatry: a blueprint for improving the mental health of young people. <i>World Psychiatry</i> , 2021, 20, 200-221.	10.4	183
65	Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. <i>World Psychiatry</i> , 2021, 20, 244-275.	10.4	76
66	Prognostic Accuracy of DSM-5 Attenuated Psychosis Syndrome in Adolescents: Prospective Real-World 5-Year Cohort Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 1663-1673.	4.3	12
67	Viewpoint European COVID-19 exit strategy for people with severe mental disorders: Too little, but not yet too late. <i>Brain, Behavior, and Immunity</i> , 2021, 94, 15-17.	4.1	17
68	Severe mental illness and European COVID-19 vaccination strategies. <i>Lancet Psychiatry</i> , 2021, 8, 356-359.	7.4	50
69	Cortical gray matter reduction precedes transition to psychosis in individuals at clinical high-risk for psychosis: A voxel-based meta-analysis. <i>Schizophrenia Research</i> , 2021, 232, 98-106.	2.0	15
70	Early intervention in psychosis during the COVID-19 pandemic: Maudsley recommendations. <i>European Neuropsychopharmacology</i> , 2021, 47, 130-135.	0.7	6
71	Risk factors for eating disorders: an umbrella review of published meta-analyses. <i>Revista Brasileira De Psiquiatria</i> , 2021, 43, 314-323.	1.7	57
72	Developing and Validating an Individualized Clinical Prediction Model to Forecast Psychotic Recurrence in Acute and Transient Psychotic Disorders: Electronic Health Record Cohort Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 1695-1705.	4.3	8

#	ARTICLE	IF	CITATIONS
73	Longitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis: a meta-analysis. <i>EClinicalMedicine</i> , 2021, 36, 100909.	7.1	25
74	A Pilot Study on Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects. <i>Brain Sciences</i> , 2021, 11, 860.	2.3	7
75	Early detection of bipolar disorders and treatment recommendations for help-seeking adolescents and young adults: Findings of the Early Detection and Intervention Center Dresden. <i>International Journal of Bipolar Disorders</i> , 2021, 9, 23.	2.2	3
76	Association of Structural Magnetic Resonance Imaging Measures With Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis. <i>JAMA Psychiatry</i> , 2021, 78, 753.	11.0	74
77	Toward Generalizable and Transdiagnostic Tools for Psychosis Prediction: An Independent Validation and Improvement of the NAPLS-2 Risk Calculator in the Multisite PRONIA Cohort. <i>Biological Psychiatry</i> , 2021, 90, 632-642.	1.3	32
78	New Electronic Health Records Screening Tools to Improve Detection of Emerging Psychosis. <i>Frontiers in Psychiatry</i> , 2021, 12, 698406.	2.6	4
79	Assessment of Psychotic Symptoms in Individuals Exposed to Very High or Extreme Altitude: A Field Study. <i>High Altitude Medicine and Biology</i> , 2021, 22, 369-378.	0.9	5
80	Risk and protective factors for cannabis, cocaine, and opioid use disorders: An umbrella review of meta-analyses of observational studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 126, 243-251.	6.1	14
81	Neurocognitive Functioning in Individuals at Clinical High Risk for Psychosis. <i>JAMA Psychiatry</i> , 2021, 78, 859.	11.0	96
82	Olfactory and gustatory dysfunctions in SARS-CoV-2 infection: A systematic review. <i>Brain, Behavior, & Immunity - Health</i> , 2021, 15, 100268.	2.5	41
83	Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis. <i>Lancet Psychiatry</i> , 2021, 8, 797-812.	7.4	202
84	Risk and protective factors for mental disorders beyond genetics: an evidence-based atlas. <i>World Psychiatry</i> , 2021, 20, 417-436.	10.4	127
85	Italian Partnership for Psychosis Prevention (ITAPP): improving the mental health of young people. <i>European Psychiatry</i> , 2021, 64, 1-21.	0.2	4
86	Probability of Transition to Psychosis in Individuals at Clinical High Risk. <i>JAMA Psychiatry</i> , 2021, 78, 970.	11.0	148
87	Disparities in Screening and Treatment of Cardiovascular Diseases in Patients With Mental Disorders Across the World: Systematic Review and Meta-Analysis of 47 Observational Studies. <i>American Journal of Psychiatry</i> , 2021, 178, 793-803.	7.2	50
88	Lack of robust meta-analytic evidence to favour cognitive behavioural therapy for prevention of psychosis. <i>World Psychiatry</i> , 2021, 20, 443-444.	10.4	5
89	Risk and Protective Factors for Personality Disorders: An Umbrella Review of Published Meta-Analyses of Case-Control and Cohort Studies. <i>Frontiers in Psychiatry</i> , 2021, 12, 679379.	2.6	13
90	Peripheral levels of C-reactive protein, tumor necrosis factor- α , interleukin-6, and interleukin- 1β across the mood spectrum in bipolar disorder: A meta-analysis of mean differences and variability. <i>Brain, Behavior, and Immunity</i> , 2021, 97, 193-203.	4.1	80

#	ARTICLE	IF	CITATIONS
91	Manifesto for an ECNP Neuromodulation Thematic Working Group (TWG): Non-invasive brain stimulation as a new Super-subspecialty. <i>European Neuropsychopharmacology</i> , 2021, 52, 72-83.	0.7	3
92	Primary prevention of depression: An umbrella review of controlled interventions. <i>Journal of Affective Disorders</i> , 2021, 294, 957-970.	4.1	23
93	Establishing a clinical service to prevent psychosis: What, how and when? Systematic review. <i>Translational Psychiatry</i> , 2021, 11, 43.	4.8	47
94	Longitudinal Course of Depressive, Anxiety, and Posttraumatic Stress Disorder Symptoms After Heart Surgery: A Meta-Analysis of 94 Studies. <i>Psychosomatic Medicine</i> , 2021, 83, 85-93.	2.0	15
95	OUP accepted manuscript. <i>Schizophrenia Bulletin</i> , 2021, , .	4.3	2
96	Proportion and predictors of remission and recovery in first-episode psychosis: Systematic review and meta-analysis. <i>European Psychiatry</i> , 2021, 64, e69.	0.2	18
97	Prevalence of Individuals at Clinical High-Risk of Psychosis in the General Population and Clinical Samples: Systematic Review and Meta-Analysis. <i>Brain Sciences</i> , 2021, 11, 1544.	2.3	29
98	Clinical outcomes in brief psychotic episodes: a systematic review and meta-analysis. <i>Epidemiology and Psychiatric Sciences</i> , 2021, 30, .	3.9	5
99	Focusing on Comorbidityâ€™A Novel Meta-Analytic Approach and Protocol to Disentangle the Specific Neuroanatomy of Co-occurring Mental Disorders. <i>Frontiers in Psychiatry</i> , 2021, 12, 807839.	2.6	5
100	No Meta-analytic Effect of Age on Probability of Developing Psychosis in Individuals at Clinical High Risk. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2021, , .	0.5	1
101	Natural Language Processing markers in first episode psychosis and people at clinical high-risk. <i>Translational Psychiatry</i> , 2021, 11, 630.	4.8	28
102	P.0178 Transition to psychosis in adolescents at clinical high risk for psychosis: a meta-analysis. <i>European Neuropsychopharmacology</i> , 2021, 53, S129-S130.	0.7	0
103	What Causes the Onset of Psychosis in Individuals at Clinical High Risk? A Meta-analysis of Risk and Protective Factors. <i>Schizophrenia Bulletin</i> , 2020, 46, 110-120.	4.3	103
104	Risk and protective factors for anxiety and obsessive-compulsive disorders: an umbrella review of systematic reviews and meta-analyses. <i>Psychological Medicine</i> , 2020, 50, 1300-1315.	4.5	27
105	Lithium Exposure During Pregnancy and the Postpartum Period: A Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. <i>American Journal of Psychiatry</i> , 2020, 177, 76-92.	7.2	83
106	Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studiesâ€™PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice. <i>Schizophrenia Bulletin</i> , 2020, 46, 432-441.	4.3	56
107	Unmet needs for treatment in 102 individuals with brief and limited intermittent psychotic symptoms (BLIPS): implications for current clinical recommendations. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e67.	3.9	23
108	Clinical Validity of <i>DSM-5</i> Attenuated Psychosis Syndrome. <i>JAMA Psychiatry</i> , 2020, 77, 311.	11.0	82

#	ARTICLE	IF	CITATIONS
109	Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4â€”839 people. <i>Lancet Psychiatry</i> , 2020, 7, 52-63.	7.4	109
110	Proportion of young people in the general population consulting general practitioners: Potential for mental health screening and prevention. <i>Microbial Biotechnology</i> , 2020, 14, 631-635.	1.7	4
111	What is good mental health? A scoping review. <i>European Neuropsychopharmacology</i> , 2020, 31, 33-46.	0.7	131
112	T97. REAL WORLD IMPLEMENTATION OF A TRANSDIAGNOSTIC RISK CALCULATOR FOR THE AUTOMATIC DETECTION OF INDIVIDUALS AT RISK OF PSYCHOSIS IN CLINICAL ROUTINE. <i>Schizophrenia Bulletin</i> , 2020, 46, S268-S268.	4.3	4
113	T109. TRAVERSING THE TRANSDIAGNOSTIC GAP BETWEEN DEPRESSION, MANIA AND PSYCHOSIS WITH NATURAL LANGUAGE PROCESSING. <i>Schizophrenia Bulletin</i> , 2020, 46, S272-S273.	4.3	0
114	S154. TOBACCO SMOKING AND CLINICAL HIGH RISK: A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EVIDENCE. <i>Schizophrenia Bulletin</i> , 2020, 46, S94-S95.	4.3	0
115	Psychosocial Intervention Without Antipsychotic Medication for Brief Psychotic Episodes?. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	3
116	Emergency department and early detection of adolescents and young adults at risk of developing mental disorders: an exploratory study. <i>Research in Psychotherapy: Psychopathology, Process and Outcome</i> , 2020, 23, 459.	0.8	2
117	Environmental risk factors, protective factors, and peripheral biomarkers for ADHD: an umbrella review. <i>Lancet Psychiatry</i> , 2020, 7, 955-970.	7.4	103
118	Outreach and support in South-London (OASIS) 2001â€”2020: Twenty years of early detection, prognosis and preventive care for young people at risk of psychosis. <i>European Neuropsychopharmacology</i> , 2020, 39, 111-122.	0.7	35
119	Aripiprazole monotherapy as transdiagnostic intervention for the treatment of mental disorders: An umbrella review according to TRANSD criteria. <i>European Neuropsychopharmacology</i> , 2020, 41, 16-27.	0.7	10
120	Psychiatric and neuropsychiatric syndromes and COVID-19 â€” Authors' reply. <i>Lancet Psychiatry</i> , 2020, 7, 664-665.	7.4	14
121	Intranasal oxytocin increases heart-rate variability in men at clinical high risk for psychosis: a proof-of-concept study. <i>Translational Psychiatry</i> , 2020, 10, 227.	4.8	16
122	Real-world digital implementation of the Psychosis Polyrisk Score (PPS): A pilot feasibility study. <i>Schizophrenia Research</i> , 2020, 226, 176-183.	2.0	11
123	DSM-5 Attenuated Psychosis Syndrome in Adolescents Hospitalized With Non-psychotic Psychiatric Disorders. <i>Frontiers in Psychiatry</i> , 2020, 11, 568982.	2.6	7
124	Universal and selective interventions to promote good mental health in young people: Systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2020, 41, 28-39.	0.7	56
125	Methodological Biases in CBT Trialâ€”Commentary: Modular Cognitive-Behavioral Therapy for Affective Symptoms in Young Individuals at Ultra-High Risk of First Episode of Psychosis: Randomized Controlled Trial. <i>Frontiers in Psychiatry</i> , 2020, 11, 394.	2.6	6
126	Prevalence and Psychosocial Correlates of Mental Health Outcomes Among Chinese College Students During the Coronavirus Disease (COVID-19) Pandemic. <i>Frontiers in Psychiatry</i> , 2020, 11, 803.	2.6	206

#	ARTICLE	IF	CITATIONS
127	Genetic Variation and Autism: A Field Synopsis and Systematic Meta-Analysis. <i>Brain Sciences</i> , 2020, 10, 692.	2.3	7
128	Towards standardising the assessment of good outcome in people at clinical high risk for psychosis: A collaborative approach. <i>Schizophrenia Research</i> , 2020, 223, 361-362.	2.0	4
129	Transdiagnostic individualized clinically-based risk calculator for the automatic detection of individuals at-risk and the prediction of psychosis: external replication in 2,430,333 US patients. <i>Translational Psychiatry</i> , 2020, 10, 364.	4.8	15
130	T127. GENDER DIFFERENCES IN CLINICAL PRESENTATION AND ILLICIT SUBSTANCE USE DURING FIRST EPISODE PSYCHOSIS: AN ELECTRONIC CASE REGISTER NATURAL LANGUAGE PROCESSING ANALYSIS. <i>Schizophrenia Bulletin</i> , 2020, 46, S278-S279.	4.3	0
131	Association between mental disorders and somatic conditions: protocol for an umbrella review. <i>Evidence-Based Mental Health</i> , 2020, 23, 135-139.	4.5	16
132	Early Intervention Services for First Episode of Psychosis in South London and the Maudsley (SLaM): 20 Years of Care and Research for Young People. <i>Frontiers in Psychiatry</i> , 2020, 11, 577110.	2.6	8
133	Real-world long-term outcomes in individuals at clinical risk for psychosis: The case for extending duration of care. <i>EClinicalMedicine</i> , 2020, 28, 100578.	7.1	29
134	Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders. <i>Translational Psychiatry</i> , 2020, 10, 152.	4.8	102
135	Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. <i>Lancet Psychiatry</i> , 2020, 7, 611-627.	7.4	1,799
136	Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. <i>World Psychiatry</i> , 2020, 19, 214-232.	10.4	167
137	Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	19
138	Dynamic Electronic Health Record Detection (DETECT) of individuals at risk of a first episode of psychosis: a case-control development and validation study. <i>The Lancet Digital Health</i> , 2020, 2, e229-e239.	12.3	44
139	Acute oxytocin effects in inferring others' beliefs and social emotions in people at clinical high risk for psychosis. <i>Translational Psychiatry</i> , 2020, 10, 203.	4.8	10
140	World/self ambivalence: A shared mechanism in different subsets of psychotic experiences? Linking symptoms with resting-state fMRI. <i>Psychiatry Research - Neuroimaging</i> , 2020, 299, 111068.	1.8	12
141	Prevention of Psychosis. <i>JAMA Psychiatry</i> , 2020, 77, 755.	11.0	287
142	Learning from COVID-19 pandemic in northern Italy: Impact on mental health and clinical care. <i>Journal of Affective Disorders</i> , 2020, 275, 78-79.	4.1	32
143	Impact of coronavirus syndromes on physical and mental health of health care workers: Systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2020, 275, 48-57.	4.1	438
144	Worldwide implementation of clinical services for the prevention of psychosis: The IEPA early intervention in mental health survey. <i>Microbial Biotechnology</i> , 2020, 14, 741-750.	1.7	58

#	ARTICLE	IF	CITATIONS
145	Prenatal and perinatal risk and protective factors for psychosis: a systematic review and meta-analysis. <i>Lancet Psychiatry</i> , 2020, 7, 399-410.	7.4	182
146	Real-World Clinical Outcomes Two Years After Transition to Psychosis in Individuals at Clinical High Risk: Electronic Health Record Cohort Study. <i>Schizophrenia Bulletin</i> , 2020, 46, 1114-1125.	4.3	11
147	Transdiagnostic Risk Calculator for the Automatic Detection of Individuals at Risk and the Prediction of Psychosis: Second Replication in an Independent National Health Service Trust. <i>Schizophrenia Bulletin</i> , 2019, 45, 562-570.	4.3	74
148	Basic Self-Disturbances Related to Reduced Anterior Cingulate Volume in Subjects at Ultra-High Risk for Psychosis. <i>Frontiers in Psychiatry</i> , 2019, 10, 254.	2.6	8
149	Development and Validation of a Dynamic Risk Prediction Model to Forecast Psychosis Onset in Patients at Clinical High Risk. <i>Schizophrenia Bulletin</i> , 2019, 46, 252-260.	4.3	13
150	Integrated Mental Health Services for the Developmental Period (0 to 25 Years): A Critical Review of the Evidence. <i>Frontiers in Psychiatry</i> , 2019, 10, 355.	2.6	109
151	Antipsychotic use and risk of life-threatening medical events: umbrella review of observational studies. <i>Acta Psychiatrica Scandinavica</i> , 2019, 140, 227-243.	4.5	59
152	Clinical-learning versus machine-learning for transdiagnostic prediction of psychosis onset in individuals at-risk. <i>Translational Psychiatry</i> , 2019, 9, 259.	4.8	21
153	Specialized services for individuals at clinical high risk for psychosis target simultaneously adolescents and young adults. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 408-409.	0.5	0
154	SSRIs and autism: interpreting an umbrella review – Authors' reply. <i>Lancet Psychiatry</i> , 2019, 6, 893-894.	7.4	0
155	Improving the Detection of Individuals at Clinical Risk for Psychosis in the Community, Primary and Secondary Care: An Integrated Evidence-Based Approach. <i>Frontiers in Psychiatry</i> , 2019, 10, 774.	2.6	57
156	European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP). <i>European Neuropsychopharmacology</i> , 2019, 29, 1301-1311.	0.7	38
157	TRANSD recommendations: improving transdiagnostic research in psychiatry. <i>World Psychiatry</i> , 2019, 18, 361-362.	10.4	29
158	The Provision of Education and Employment Support At the Outreach and Support in South London (OASIS) Service for People at Clinical High Risk for Psychosis. <i>Frontiers in Psychiatry</i> , 2019, 10, 799.	2.6	6
159	Development of a Self-Administered Questionnaire to Detect Psychosis at High Altitude: The HAPSY Questionnaire. <i>High Altitude Medicine and Biology</i> , 2019, 20, 352-360.	0.9	1
160	Risk factors for posttraumatic stress disorder: An umbrella review of systematic reviews and meta-analyses. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 107, 154-165.	6.1	115
161	Association of Antidepressant Use With Adverse Health Outcomes. <i>JAMA Psychiatry</i> , 2019, 76, 1241.	11.0	143
162	Unmet needs in patients with brief psychotic disorders: Too ill for clinical high risk services and not ill enough for first episode services. <i>European Psychiatry</i> , 2019, 57, 26-32.	0.2	34

#	ARTICLE	IF	CITATIONS
163	Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis. <i>Neuropsychopharmacology</i> , 2019, 44, 1300-1309.	5.4	26
164	Research Perspectives for Neuroimaging of Schizophrenia Spectrum Disorders. , 2019, , 303-325.		0
165	Neuroimaging and the Longitudinal Course of Schizophrenia. , 2019, , 183-218.		0
166	Neuroimaging and the At-Risk Mental State. , 2019, , 219-265.		1
167	Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis. <i>Frontiers in Psychiatry</i> , 2019, 10, 345.	2.6	29
168	Environmental risk factors and biomarkers for autism spectrum disorder: an umbrella review of the evidence. <i>Lancet Psychiatry</i> , 2019, 6, 590-600.	7.4	169
169	Association of antidepressants with brain morphology in early stages of psychosis: an imaging genomics approach. <i>Scientific Reports</i> , 2019, 9, 8516.	3.3	10
170	Psychosis Polyrisk Score (PPS) for the Detection of Individuals At-Risk and the Prediction of Their Outcomes. <i>Frontiers in Psychiatry</i> , 2019, 10, 174.	2.6	45
171	Transdiagnostic psychiatry: a systematic review. <i>World Psychiatry</i> , 2019, 18, 192-207.	10.4	218
172	Transdiagnostic Individualized Clinically Based Risk Calculator for the Detection of Individuals at Risk and the Prediction of Psychosis: Model Refinement Including Nonlinear Effects of Age. <i>Frontiers in Psychiatry</i> , 2019, 10, 313.	2.6	16
173	Short clinically-based prediction model to forecast transition to psychosis in individuals at clinical high risk state. <i>European Psychiatry</i> , 2019, 58, 72-79.	0.2	9
174	F94. EFFECTS OF OXYTOCIN ON NEUROCHEMICAL METABOLITES IN PSYCHOSIS RISK. <i>Schizophrenia Bulletin</i> , 2019, 45, S289-S290.	4.3	0
175	O6.5. INVESTIGATING VARIABLES FROM THE NAPLS RISK CALCULATOR FOR PSYCHOSIS IN THE EU-GEI HIGH RISK STUDY. <i>Schizophrenia Bulletin</i> , 2019, 45, S177-S178.	4.3	0
176	Neurochemical effects of oxytocin in people at clinical high risk for psychosis. <i>European Neuropsychopharmacology</i> , 2019, 29, 601-615.	0.7	8
177	Towards a framework for good outcome in people at clinical high risk for psychosis: A Delphi consensus study. <i>Schizophrenia Research</i> , 2019, 208, 209-216.	2.0	7
178	Real World Implementation of a Transdiagnostic Risk Calculator for the Automatic Detection of Individuals at Risk of Psychosis in Clinical Routine: Study Protocol. <i>Frontiers in Psychiatry</i> , 2019, 10, 109.	2.6	39
179	Meta-analysis of Voxel-Based Neuroimaging Studies using Seed-based Mapping with Permutation of Subject Images (SDM-PSI). <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	56
180	Pan-London Network for Psychosis-Prevention (PNP). <i>Frontiers in Psychiatry</i> , 2019, 10, 707.	2.6	24

#	ARTICLE	IF	CITATIONS
181	Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence). <i>Frontiers in Psychiatry</i> , 2019, 10, 764.	2.6	72
182	The relationship between ethnicity and service access, treatment uptake and the incidence of psychosis among people at ultra high risk for psychosis. <i>Psychiatry Research</i> , 2019, 272, 618-627.	3.3	11
183	E-Clinical High Risk for Psychosis: Viewpoint on Potential of Digital Innovations for Preventive Psychiatry. <i>JMIR Mental Health</i> , 2019, 6, e14581.	3.3	16
184	Gamma band oscillations in the early phase of psychosis: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 90, 381-399.	6.1	45
185	Potential Reporting Bias in Neuroimaging Studies of Sex Differences. <i>Scientific Reports</i> , 2018, 8, 6082.	3.3	109
186	What causes psychosis? An umbrella review of risk and protective factors. <i>World Psychiatry</i> , 2018, 17, 49-66.	10.4	387
187	The Hype Cycle of the Clinical High Risk State for Psychosis: The Need of a Refined Approach. <i>Schizophrenia Bulletin</i> , 2018, 44, 250-253.	4.3	22
188	Meta-analytical prognostic accuracy of the Comprehensive Assessment of at Risk Mental States (CAARMS): The need for refined prediction. <i>European Psychiatry</i> , 2018, 49, 62-68.	0.2	39
189	Can We Reduce the Duration of Untreated Psychosis? A Systematic Review and Meta-Analysis of Controlled Interventional Studies. <i>Schizophrenia Bulletin</i> , 2018, 44, 1362-1372.	4.3	100
190	Diagnostic and Prognostic Significance of DSM-5 Attenuated Psychosis Syndrome in Services for Individuals at Ultra High Risk for Psychosis. <i>Schizophrenia Bulletin</i> , 2018, 44, 264-275.	4.3	26
191	Neighbourhood deprivation is positively associated with detection of the ultra-high risk (UHR) state for psychosis in South East London. <i>Schizophrenia Research</i> , 2018, 192, 371-376.	2.0	15
192	Why transition risk to psychosis is not declining at the OASIS ultra high risk service: The hidden role of stable pretest risk enrichment. <i>Schizophrenia Research</i> , 2018, 192, 385-390.	2.0	45
193	Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 185-196.	1.9	18
194	A systematic review and meta-analysis of mental health service use in people who report psychotic experiences. <i>Microbial Biotechnology</i> , 2018, 12, 275-285.	1.7	30
195	34.2 IMPROVING THE DETECTION OF INDIVIDUALS AT RISK OF PSYCHOSIS IN SECONDARY MENTAL HEALTH CARE. <i>Schizophrenia Bulletin</i> , 2018, 44, S56-S57.	4.3	0
196	T122. UNMET NEEDS IN PATIENTS WITH ACUTE TRANSIENT PSYCHOTIC DISORDERS (ATPD): ANALYSIS OF PATHWAYS TO CARE: AN 8 YEARS FOLLOW-UP STUDY. <i>Schizophrenia Bulletin</i> , 2018, 44, S162-S163.	4.3	0
197	S126. GOOD OUTCOME IN INDIVIDUALS AT ULTRA-HIGH RISK (UHR) OF DEVELOPING PSYCHOSIS: A DELPHI STUDY. <i>Schizophrenia Bulletin</i> , 2018, 44, S374-S374.	4.3	0
198	Response to the commentary by Buoli et al., EURPSY-D-18-00265. <i>European Psychiatry</i> , 2018, 54, 100-101.	0.2	0

#	ARTICLE	IF	CITATIONS
199	A Case of a College Student Presenting With Mild Mental Health Problems. <i>JAMA Psychiatry</i> , 2018, 75, 1298.	11.0	17
200	The Science of Prognosis in Psychiatry. <i>JAMA Psychiatry</i> , 2018, 75, 1289.	11.0	151
201	Long term outcomes of acute and transient psychotic disorders: The missed opportunity of preventive interventions. <i>European Psychiatry</i> , 2018, 52, 126-133.	0.2	32
202	Semistructured Interview for Bipolar At Risk States (SIBARS). <i>Psychiatry Research</i> , 2018, 264, 302-309.	3.3	36
203	Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis. <i>World Psychiatry</i> , 2018, 17, 196-209.	10.4	183
204	Efficacy and Acceptability of Interventions for Attenuated Positive Psychotic Symptoms in Individuals at Clinical High Risk of Psychosis: A Network Meta-Analysis. <i>Frontiers in Psychiatry</i> , 2018, 9, 187.	2.6	87
205	Impact on the Onset of Psychosis of a Polygenic Schizophrenia-Related Risk Score and Changes in White Matter Volume. <i>Cellular Physiology and Biochemistry</i> , 2018, 48, 1201-1214.	1.6	10
206	34. IMPROVING THE DETECTION OF INDIVIDUALS AT RISK OF PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S55-S56.	4.3	0
207	Ten simple rules for conducting umbrella reviews. <i>Evidence-Based Mental Health</i> , 2018, 21, 95-100.	4.5	317
208	F256. CAN WE REDUCE THE DURATION OF UNTREATED PSYCHOSIS?. <i>Schizophrenia Bulletin</i> , 2018, 44, S323-S323.	4.3	0
209	S149. EFFECTS OF INTRANASAL OXYTOCIN ON RESTING CEREBRAL BLOOD FLOW IN PEOPLE AT ULTRA-HIGH RISK FOR PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S383-S383.	4.3	0
210	What Is an Attenuated Psychotic Symptom? On the Importance of the Context. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw182.	4.3	49
211	Improving Prognostic Accuracy in Subjects at Clinical High Risk for Psychosis: Systematic Review of Predictive Models and Meta-analytical Sequential Testing Simulation. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw098.	4.3	98
212	Structural Network Disorganization in Subjects at Clinical High Risk for Psychosis. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw110.	4.3	38
213	Using neuroimaging to help predict the onset of psychosis. <i>NeuroImage</i> , 2017, 145, 209-217.	4.2	54
214	Diagnostic and Prognostic Significance of Brief Limited Intermittent Psychotic Symptoms (BLIPS) in Individuals at Ultra High Risk. <i>Schizophrenia Bulletin</i> , 2017, 43, 48-56.	4.3	106
215	The Clinical High-Risk State for Psychosis (CHR-P), Version II. <i>Schizophrenia Bulletin</i> , 2017, 43, 44-47.	4.3	169
216	Long-term validity of the At Risk Mental State (ARMS) for predicting psychotic and non-psychotic mental disorders. <i>European Psychiatry</i> , 2017, 42, 49-54.	0.2	104

#	ARTICLE	IF	CITATIONS
217	Negative Psychosis Prevention Trials. <i>JAMA Psychiatry</i> , 2017, 74, 651.	11.0	12
218	Longitudinal alterations in motivational salience processing in ultra-high-risk subjects for psychosis. <i>Psychological Medicine</i> , 2017, 47, 243-254.	4.5	34
219	Why ultra high risk criteria for psychosis prediction do not work well outside clinical samples and what to do about it. <i>World Psychiatry</i> , 2017, 16, 212-213.	10.4	45
220	Diagnostic validity of ICD-10 acute and transient psychotic disorders and DSM-5 brief psychotic disorder. <i>European Psychiatry</i> , 2017, 45, 104-113.	0.2	41
221	Extending the Benefits of Indicated Prevention to Improve Outcomes of First-Episode Psychosis. <i>JAMA Psychiatry</i> , 2017, 74, 667.	11.0	48
222	Development and Validation of a Clinically Based Risk Calculator for the Transdiagnostic Prediction of Psychosis. <i>JAMA Psychiatry</i> , 2017, 74, 493.	11.0	206
223	Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies. <i>Annals of Neurology</i> , 2017, 81, 171-180.	5.3	77
224	Deconstructing Vulnerability for Psychosis: Meta-Analysis of Environmental Risk Factors for Psychosis in Subjects at Ultra High-Risk. <i>European Psychiatry</i> , 2017, 40, 65-75.	0.2	241
225	Improving outcomes of first-episode psychosis: an overview. <i>World Psychiatry</i> , 2017, 16, 251-265.	10.4	363
226	People meeting ultra high risk for psychosis criteria in the community. <i>World Psychiatry</i> , 2017, 16, 322-323.	10.4	7
227	Formal thought disorder in people at ultra-high risk of psychosis. <i>BJPsych Open</i> , 2017, 3, 165-170.	0.7	19
228	Pattern of activation during delayed matching to sample task predicts functional outcome in people at ultra high risk for psychosis. <i>Schizophrenia Research</i> , 2017, 181, 86-93.	2.0	7
229	Age-related brain structural alterations as an intermediate phenotype of psychosis. <i>Journal of Psychiatry and Neuroscience</i> , 2017, 42, 307-319.	2.4	32
230	Altered activation and connectivity in a hippocampal-basal ganglia-midbrain circuit during salience processing in subjects at ultra high risk for psychosis. <i>Translational Psychiatry</i> , 2017, 7, e1245-e1245.	4.8	47
231	Towards a Standard Psychometric Diagnostic Interview for Subjects at Ultra High Risk of Psychosis: CAARMS versus SIPS. <i>Psychiatry Journal</i> , 2016, 2016, 1-11.	1.5	97
232	Prison and Community Populations at Ultra-High Risk of Psychosis: Differences and Challenges for Service Provision. <i>Psychiatric Services</i> , 2016, 67, 990-995.	2.0	4
233	Predicting the onset of psychosis in patients at clinical high risk: practical guide to probabilistic prognostic reasoning. <i>Evidence-Based Mental Health</i> , 2016, 19, 10-15.	4.5	58
234	Peripheral oxytocin and vasopressin: Biomarkers of psychiatric disorders? A comprehensive systematic review and preliminary meta-analysis. <i>Psychiatry Research</i> , 2016, 241, 207-220.	3.3	119

#	ARTICLE	IF	CITATIONS
235	Persistence or recurrence of non-psychotic comorbid mental disorders associated with 6-year poor functional outcomes in patients at ultra high risk for psychosis. <i>Journal of Affective Disorders</i> , 2016, 203, 101-110.	4.1	120
236	Authors' reply. <i>British Journal of Psychiatry</i> , 2016, 208, 197-198.	2.8	0
237	Services for people at high risk improve outcomes in patients with first episode psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2016, 133, 76-85.	4.5	44
238	Forty years of structural imaging in psychosis: promises and truth. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 207-224.	4.5	40
239	Deconstructing Pretest Risk Enrichment to Optimize Prediction of Psychosis in Individuals at Clinical High Risk. <i>JAMA Psychiatry</i> , 2016, 73, 1260.	11.0	111
240	The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis. <i>Schizophrenia Bulletin</i> , 2016, 42, 732-743.	4.3	183
241	Prognosis of Brief Psychotic Episodes. <i>JAMA Psychiatry</i> , 2016, 73, 211.	11.0	137
242	Intensive community outreach for those at ultra high risk of psychosis: dilution, not solution. <i>Lancet Psychiatry</i> , 2016, 3, 18.	7.4	26
243	Prevalence and implications of Truman symptoms in subjects at ultra high risk for psychosis. <i>Psychiatry Research</i> , 2016, 238, 270-276.	3.3	13
244	The Psychosis High-Risk State. <i>Key Issues in Mental Health</i> , 2016, , 55-68.	0.6	4
245	Diagnostic Stability of ICD/DSM First Episode Psychosis Diagnoses: Meta-analysis. <i>Schizophrenia Bulletin</i> , 2016, 42, 1395-1406.	4.3	151
246	Altering the course of schizophrenia: progress and perspectives. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 485-515.	46.4	410
247	Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk. <i>JAMA Psychiatry</i> , 2016, 73, 113.	11.0	354
248	An initial investigation of abnormal bodily phenomena in subjects at ultra high risk for psychosis: Their prevalence and clinical implications. <i>Comprehensive Psychiatry</i> , 2016, 66, 39-45.	3.1	13
249	Neurobiological Models of Self-Disorders in Early Schizophrenia. <i>Schizophrenia Bulletin</i> , 2016, 42, 874-880.	4.3	36
250	Identifying children and adolescents at ultra high risk of psychosis in Italian neuropsychiatry services: a feasibility study. <i>European Child and Adolescent Psychiatry</i> , 2016, 25, 91-106.	4.7	37
251	Dysfunctional insular connectivity during reward prediction in patients with first-episode psychosis. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, 367-376.	2.4	36
252	At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. <i>World Psychiatry</i> , 2015, 14, 322-332.	10.4	209

#	ARTICLE	IF	CITATIONS
253	Brain Diffusion Changes in Emerging Psychosis and the Impact of State-Dependent Psychopathology. <i>NeuroSignals</i> , 2015, 23, 71-83.	0.9	26
254	The impact of delivering <sc>GP</sc> training on the clinical high risk and first-episode psychosis on referrals and pathways to care. <i>Microbial Biotechnology</i> , 2015, 9, 459-466.	1.7	11
255	Antidepressant, antipsychotic and psychological interventions in subjects at high clinical risk for psychosis: OASIS 6-year naturalistic study. <i>Psychological Medicine</i> , 2015, 45, 1327-1339.	4.5	60
256	Sensory gating deficits in the attenuated psychosis syndrome. <i>Schizophrenia Research</i> , 2015, 161, 277-282.	2.0	11
257	Medial frontal gyrus alterations in schizophrenia: Relationship with duration of illness and executive dysfunction. <i>Psychiatry Research - Neuroimaging</i> , 2015, 231, 103-110.	1.8	28
258	Orbitofrontal response to drug-related stimuli after heroin administration. <i>Addiction Biology</i> , 2015, 20, 570-579.	2.6	32
259	Gray Matter Reductions in Cortical Midline Structures Related to Basic Self Disturbances in People at "ultra High Risk" for Psychosis. <i>European Psychiatry</i> , 2015, 30, 297.	0.2	0
260	Duration of untreated psychosis and need for admission in patients who engage with mental health services in the prodromal phase. <i>British Journal of Psychiatry</i> , 2015, 207, 130-134.	2.8	65
261	Modulation of motivational salience processing during the early stages of psychosis. <i>Schizophrenia Research</i> , 2015, 166, 17-23.	2.0	44
262	Neurophysiological effects of acute oxytocin administration: systematic review and meta-analysis of placebo-controlled imaging studies. <i>Journal of Psychiatry and Neuroscience</i> , 2015, 40, E1-E22.	2.4	159
263	Speed of Psychosis Progression in People at Ultra-High Clinical Risk. <i>JAMA Psychiatry</i> , 2015, 72, 622.	11.0	69
264	Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. <i>Schizophrenia Bulletin</i> , 2015, 41, 892-899.	4.3	505
265	BDNF Val66Met polymorphism and hippocampal volume in neuropsychiatric disorders: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 55, 107-118.	6.1	118
266	Predictors of functional outcome in individuals at high clinical risk for psychosis at six years follow-up. <i>Journal of Psychiatric Research</i> , 2015, 65, 115-123.	3.1	40
267	The Enduring Search for the Koplik Spots of Psychosis. <i>JAMA Psychiatry</i> , 2015, 72, 863.	11.0	14
268	Bullying victimisation and paranoid ideation in people at ultra high risk for psychosis. <i>Schizophrenia Research</i> , 2015, 168, 68-73.	2.0	46
269	Why are help-seeking subjects at ultra-high risk for psychosis help-seeking?. <i>Psychiatry Research</i> , 2015, 228, 808-815.	3.3	111
270	Disorder, not just state of risk: Meta-analysis of functioning and quality of life in people at high risk of psychosis. <i>British Journal of Psychiatry</i> , 2015, 207, 198-206.	2.8	226

#	ARTICLE	IF	CITATIONS
271	Hippocampal volume correlates with attenuated negative psychotic symptoms irrespective of antidepressant medication. <i>NeuroImage: Clinical</i> , 2015, 8, 230-237.	2.7	13
272	Ventral Striatal Activation During Reward Processing in Psychosis. <i>JAMA Psychiatry</i> , 2015, 72, 1243.	11.0	282
273	Functional Outcome in People at High Risk for Psychosis Predicted by Thalamic Glutamate Levels and Prefronto-Striatal Activation. <i>Schizophrenia Bulletin</i> , 2015, 41, 429-439.	4.3	59
274	Anisotropic Kernels for Coordinate-Based Meta-Analyses of Neuroimaging Studies. <i>Frontiers in Psychiatry</i> , 2014, 5, 13.	2.6	286
275	Neuroanatomical markers of genetic liability to psychosis and first episode psychosis: A voxelwise meta-analytical comparison. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 219-228.	2.6	83
276	Lessons learned from the psychosis high-risk state: towards a general staging model of prodromal intervention. <i>Psychological Medicine</i> , 2014, 44, 17-24.	4.5	174
277	Abnormal effective connectivity and psychopathological symptoms in the psychosis high-risk state. <i>Journal of Psychiatry and Neuroscience</i> , 2014, 39, 239-248.	2.4	39
278	Evidence of reporting biases in voxel-based morphometry (VBM) studies of psychiatric and neurological disorders. <i>Human Brain Mapping</i> , 2014, 35, 3052-3065.	3.6	50
279	Neurofunctional maps of the "maternal brain"™ and the effects of oxytocin: A multimodal voxel-based meta-analysis. <i>Psychiatry and Clinical Neurosciences</i> , 2014, 68, 733-751.	1.8	48
280	Cannabis use and transition to psychosis in people at ultra-high risk. <i>Psychological Medicine</i> , 2014, 44, 2503-2512.	4.5	83
281	Are we really mapping psychosis risk? Neuroanatomical signature of affective disorders in subjects at ultra high risk. <i>Psychological Medicine</i> , 2014, 44, 3491-3501.	4.5	37
282	White Matter Alterations in Early Stages of Schizophrenia: A Systematic Review of Diffusion Tensor Imaging Studies. <i>Journal of Neuroimaging</i> , 2014, 24, 101-110.	2.0	201
283	THE PSYCHOSIS HIGH RISK STATE: IS IT VALID?. <i>Schizophrenia Research</i> , 2014, 153, S23-S24.	2.0	0
284	Dopaminergic basis of salience dysregulation in psychosis. <i>Trends in Neurosciences</i> , 2014, 37, 85-94.	8.6	204
285	Cannabidiol as a potential treatment for psychosis. <i>European Neuropsychopharmacology</i> , 2014, 24, 51-64.	0.7	75
286	Publication and other reporting biases in cognitive sciences: detection, prevalence, and prevention. <i>Trends in Cognitive Sciences</i> , 2014, 18, 235-241.	7.8	361
287	Comorbid Depressive and Anxiety Disorders in 509 Individuals With an At-Risk Mental State: Impact on Psychopathology and Transition to Psychosis. <i>Schizophrenia Bulletin</i> , 2014, 40, 120-131.	4.3	499
288	Attenuated Psychosis Syndrome: Ready for DSM-5.1?. <i>Annual Review of Clinical Psychology</i> , 2014, 10, 155-192.	12.3	119

#	ARTICLE	IF	CITATIONS
289	Multimodal voxel-based meta-analysis of structural and functional magnetic resonance imaging studies in those at elevated genetic risk of developing schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2014, 221, 69-77.	1.8	94
290	Polyunsaturated fatty acids in emerging psychosis: a safer alternative?. <i>Microbial Biotechnology</i> , 2014, 8, 199-208.	1.7	28
291	Approaching a network connectivity-driven classification of the psychosis continuum: a selective review and suggestions for future research. <i>Frontiers in Human Neuroscience</i> , 2014, 8, 1047.	2.0	56
292	Effects of Cannabis on Neurocognitive Functioning: Recent Advances, Neurodevelopmental Influences, and Sex Differences. <i>Neuropsychology Review</i> , 2013, 23, 117-137.	4.9	252
293	Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 1680-1691.	6.1	434
294	Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: A critical review. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 412-431.	2.6	69
295	Is cannabis neurotoxic for the healthy brain? A meta-analytical review of structural brain alterations in non-psychotic users. <i>Psychiatry and Clinical Neurosciences</i> , 2013, 67, 483-492.	1.8	88
296	Moving beyond transition outcomes: Meta-analysis of remission rates in individuals at high clinical risk for psychosis. <i>Psychiatry Research</i> , 2013, 209, 266-272.	3.3	114
297	Antipsychotics' effects on blood levels of cytokines in schizophrenia: A meta-analysis. <i>Schizophrenia Research</i> , 2013, 151, 43-47.	2.0	190
298	One Century of Allgemeine Psychopathologie (1913 to 2013) by Karl Jaspers. <i>Schizophrenia Bulletin</i> , 2013, 39, 268-269.	4.3	6
299	Striatal Presynaptic Dopamine in Schizophrenia, Part I: Meta-Analysis of Dopamine Active Transporter (DAT) Density. <i>Schizophrenia Bulletin</i> , 2013, 39, 22-32.	4.3	104
300	At Risk for Schizophrenic or Affective Psychoses? A Meta-Analysis of DSM/ICD Diagnostic Outcomes in Individuals at High Clinical Risk. <i>Schizophrenia Bulletin</i> , 2013, 39, 923-932.	4.3	165
301	Lost in transition: setting the psychosis threshold in prodromal research. <i>Acta Psychiatrica Scandinavica</i> , 2013, 127, 248-252.	4.5	55
302	Psychopathological symptoms in child and adolescent migraine and tension-type headache: A meta-analysis. <i>Cephalalgia</i> , 2013, 33, 112-122.	3.9	86
303	Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 3-13.	3.2	40
304	Outreach and support in South London (OASIS), 2001-2011: Ten years of early diagnosis and treatment for young individuals at high clinical risk for psychosis. <i>European Psychiatry</i> , 2013, 28, 315-326.	0.2	172
305	Prevalence of self-reported childhood abuse in psychosis: A meta-analysis of retrospective studies. <i>Psychiatry Research</i> , 2013, 210, 8-15.	3.3	144
306	Long-acting injectable antipsychotics in early psychosis: a literature review. <i>Microbial Biotechnology</i> , 2013, 7, 247-254.	1.7	46

#	ARTICLE	IF	CITATIONS
307	The Phenomenology and Neurobiology of Delusion Formation During Psychosis Onset: Jaspers, Truman Symptoms, and Aberrant Salience. <i>Schizophrenia Bulletin</i> , 2013, 39, 278-286.	4.3	99
308	The Psychosis High-Risk State. <i>JAMA Psychiatry</i> , 2013, 70, 107.	11.0	1,222
309	Negative psychotic symptoms and impaired role functioning predict transition outcomes in the at-risk mental state: a latent class cluster analysis study. <i>Psychological Medicine</i> , 2013, 43, 2311-2325.	4.5	95
310	Tracking cerebral white matter changes across the lifespan: insights from diffusion tensor imaging studies. <i>Journal of Neural Transmission</i> , 2013, 120, 1369-1395.	2.8	97
311	Oligodendroglial Alterations and the Role of Microglia in White Matter Injury: Relevance to Schizophrenia. <i>Developmental Neuroscience</i> , 2013, 35, 102-129.	2.0	122
312	Long-Chain Omega-3 Fatty Acids and Psychotic Disorders. , 2013, , 149-178.		0
313	Striatal Presynaptic Dopamine in Schizophrenia, Part II: Meta-Analysis of [18F/11C]-DOPA PET Studies. <i>Schizophrenia Bulletin</i> , 2013, 39, 33-42.	4.3	224
314	Efficacy and safety of second-generation long-acting injections in schizophrenia. <i>International Clinical Psychopharmacology</i> , 2013, 28, 57-66.	1.7	83
315	Brain Connectivity Abnormalities Predating the Onset of Psychosis. <i>JAMA Psychiatry</i> , 2013, 70, 903.	11.0	94
316	Patientsâ€™ and cliniciansâ€™ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis. <i>Therapeutic Advances in Psychopharmacology</i> , 2013, 3, 89-99.	2.7	53
317	Cannabis affects people differently: inter-subject variation in the psychotogenic effects of δ^9 -tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers. <i>Psychological Medicine</i> , 2013, 43, 1255-1267.	4.5	51
318	Neuropsychopharmacology of auditory hallucinations: insights from pharmacological functional MRI and perspectives for future research. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 23-36.	2.8	9
319	A General Approach for Combining Voxel-Based Meta-Analyses Conducted in Different Neuroimaging Modalities. <i>Current Medicinal Chemistry</i> , 2013, 20, 462-466.	2.4	2
320	Potential Reporting Bias in fMRI Studies of the Brain. <i>PLoS ONE</i> , 2013, 8, e70104.	2.5	110
321	Structural and Functional Imaging Studies in Chronic Cannabis Users: A Systematic Review of Adolescent and Adult Findings. <i>PLoS ONE</i> , 2013, 8, e55821.	2.5	334
322	A General Approach for Combining Voxel-Based Meta-Analyses Conducted in Different Neuroimaging Modalities. <i>Current Medicinal Chemistry</i> , 2013, 20, 462-466.	2.4	40
323	A general approach for combining voxel-based meta-analyses conducted in different neuroimaging modalities. <i>Current Medicinal Chemistry</i> , 2013, 20, 462-6.	2.4	48
324	Mapping vulnerability to bipolar disorder: a systematic review and meta-analysis of neuroimaging studies. <i>Journal of Psychiatry and Neuroscience</i> , 2012, 37, 170-184.	2.4	112

#	ARTICLE	IF	CITATIONS
325	Voxel-wise meta-analysis of fMRI studies in patients at clinical high risk for psychosis. <i>Journal of Psychiatry and Neuroscience</i> , 2012, 37, 106-112.	2.4	51
326	Eicosapentaenoic Acid Interventions in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 179-185.	1.4	109
327	Neuroanatomical Maps of Psychosis Onset: Voxel-wise Meta-Analysis of Antipsychotic-Naive VBM Studies. <i>Schizophrenia Bulletin</i> , 2012, 38, 1297-1307.	4.3	254
328	Cognitive Functioning in Prodromal Psychosis. <i>Archives of General Psychiatry</i> , 2012, 69, 562-71.	12.3	567
329	Induction of Psychosis by δ^9 -Tetrahydrocannabinol Reflects Modulation of Prefrontal and Striatal Function During Attentional Salience Processing. <i>Archives of General Psychiatry</i> , 2012, 69, 27.	12.3	193
330	Predicting Psychosis. <i>Archives of General Psychiatry</i> , 2012, 69, 220.	12.3	1,214
331	Polysaturated Fatty Acids in Emerging Psychosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 576-591.	1.9	16
332	Neurophysiological Alterations in the Prepsychotic Phases. <i>Current Pharmaceutical Design</i> , 2012, 18, 479-485.	1.9	7
333	Transition to Psychosis Associated With Prefrontal and Subcortical Dysfunction in Ultra High-Risk Individuals. <i>Schizophrenia Bulletin</i> , 2012, 38, 1268-1276.	4.3	120
334	Striatal Dopamine Transporter Alterations in ADHD: Pathophysiology or Adaptation to Psychostimulants? A Meta-Analysis. <i>American Journal of Psychiatry</i> , 2012, 169, 264-272.	7.2	198
335	Sabina Spielrein. <i>American Journal of Psychiatry</i> , 2012, 169, 21-21.	7.2	0
336	Basic Symptoms and the Prediction of First-Episode Psychosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 351-357.	1.9	152
337	Abnormal Relationship Between Medial Temporal Lobe and Subcortical Dopamine Function in People With an Ultra High Risk for Psychosis. <i>Schizophrenia Bulletin</i> , 2012, 38, 1040-1049.	4.3	71
338	Effects of Antipsychotics on Dentate Gyrus Stem Cell Proliferation and Survival in Animal Models: A Critical Update. <i>Neural Plasticity</i> , 2012, 2012, 1-12.	2.2	12
339	Interpersonal sensitivity in the at-risk mental state for psychosis. <i>Psychological Medicine</i> , 2012, 42, 1835-1845.	4.5	63
340	Insular volume abnormalities associated with different transition probabilities to psychosis. <i>Psychological Medicine</i> , 2012, 42, 1613-1625.	4.5	50
341	Biochemical Markers of Impending Psychosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 505-509.	1.9	3
342	Genetic Vulnerability to Psychosis and Cortical Function: Epistatic Effects between DAAO and G72. <i>Current Pharmaceutical Design</i> , 2012, 18, 510-517.	1.9	12

#	ARTICLE	IF	CITATIONS
343	Glutamate and Psychosis Risk. <i>Current Pharmaceutical Design</i> , 2012, 18, 466-478.	1.9	34
344	Predicting the development of schizophrenia. <i>British Journal of Psychiatry</i> , 2012, 200, 254-255.	2.8	4
345	The Relationship of Developmental Changes in White Matter to the Onset of Psychosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 422-433.	1.9	30
346	Relationship Between Gyrfication and Functional Connectivity of the Prefrontal Cortex in Subjects at High Genetic Risk of Schizophrenia. <i>Current Pharmaceutical Design</i> , 2012, 18, 434-442.	1.9	35
347	Economic Impact of Early Detection and Early Intervention of Psychosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 592-595.	1.9	21
348	The Vulnerability to Schizophrenia Mainstream Research Paradigms and Phenomenological Directions. <i>Current Pharmaceutical Design</i> , 2012, 18, 338-345.	1.9	11
349	Cognitive Remediation in the Early Course of Schizophrenia: A Critical Review. <i>Current Pharmaceutical Design</i> , 2012, 18, 534-541.	1.9	28
350	Reliability and Validity of the Comprehensive Assessment of the at Risk Mental State, Italian Version (CAARMS-I). <i>Current Pharmaceutical Design</i> , 2012, 18, 386-391.	1.9	19
351	Editorial [Prodromal Psychosis: Diagnosis and Treatment (Executive Guest Editor: Paolo Fusar-Poli)]. <i>Current Pharmaceutical Design</i> , 2012, 18, 337-337.	1.9	2
352	Ethical Implications for Clinical Practice and Future Research in "At Risk" Individuals. <i>Current Pharmaceutical Design</i> , 2012, 18, 606-612.	1.9	10
353	From the Prodrome to Chronic Schizophrenia: The Neurobiology Underlying Psychotic Symptoms and Cognitive Impairments. <i>Current Pharmaceutical Design</i> , 2012, 18, 459-465.	1.9	51
354	Neuroimaging and Resilience Factors - Staging of the At-risk Mental State?. <i>Current Pharmaceutical Design</i> , 2012, 18, 416-421.	1.9	12
355	The Ultra High Risk Approach to Define Psychosis Risk. <i>Current Pharmaceutical Design</i> , 2012, 18, 346-350.	1.9	20
356	Immigration, Social Environment and Onset of Psychotic Disorders. <i>Current Pharmaceutical Design</i> , 2012, 18, 518-526.	1.9	54
357	Philosophical Issues in the Prodromal Phase of Psychosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 596-605.	1.9	9
358	Cannabis Abuse and Vulnerability to Psychosis: Targeting Preventive Services. <i>Current Pharmaceutical Design</i> , 2012, 18, 542-549.	1.9	7
359	Response to Spencer et al. Letter. <i>American Journal of Psychiatry</i> , 2012, 169, 666-666.	7.2	2
360	Can We Detect Psychotic-like Experiences in the General Population?. <i>Current Pharmaceutical Design</i> , 2012, 18, 376-385.	1.9	44

#	ARTICLE	IF	CITATIONS
361	Brain Structural Abnormalities at the Onset of Schizophrenia and Bipolar Disorder: A Meta-analysis of Controlled Magnetic Resonance Imaging Studies. <i>Current Pharmaceutical Design</i> , 2012, 18, 486-494.	1.9	144
362	Episodic Memory Dysfunction in Individuals at High-Risk of Psychosis: A Systematic Review of Neuropsychological and Neurofunctional Studies. <i>Current Pharmaceutical Design</i> , 2012, 18, 443-458.	1.9	25
363	Third-generation neuroimaging in early schizophrenia: Translating research evidence into clinical utility. <i>British Journal of Psychiatry</i> , 2012, 200, 270-272.	2.8	34
364	Should attenuated psychosis syndrome be included in DSM-5?. <i>Lancet, The</i> , 2012, 379, 591-592.	13.7	55
365	Mapping prodromal psychosis: A critical review of neuroimaging studies. <i>European Psychiatry</i> , 2012, 27, 181-191.	0.2	70
366	Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication. <i>Neuroscience and Biobehavioral Reviews</i> , 2012, 36, 2325-2333.	6.1	311
367	Presynaptic dopamine alterations in schizophrenia: Functional or structural defect?. <i>Psychiatry Research - Neuroimaging</i> , 2012, 202, 271-272.	1.8	0
368	Gray matter pathology of hippocampus â€“ A specific endophenotype for schizophrenia?. <i>Psychiatry Research - Neuroimaging</i> , 2012, 202, 273-274.	1.8	3
369	Poster #184 CANNABIS USE IN PATIENTS AT CLINICAL HIGH RISK OF PSYCHOSIS: IMPACT ON PRODROMAL SYMPTOMS AND TRANSITION TO PSYCHOSIS â€“ A SYSTEMATIC REVIEW. <i>Schizophrenia Research</i> , 2012, 136, S347.	2.0	0
370	Whither the Attenuated Psychosis Syndrome?. <i>Schizophrenia Bulletin</i> , 2012, 38, 1130-1134.	4.3	85
371	Why are psychiatric imaging methods clinically unreliable? Conclusions and practical guidelines for authors, editors and reviewers. <i>Behavioral and Brain Functions</i> , 2012, 8, 46.	3.3	27
372	THALAMIC GLUTAMATE LEVELS AS A PREDICTOR OF CORTICAL RESPONSE DURING EXECUTIVE FUNCTIONING IN SUBJECTS AT HIGH RISK FOR PSYCHOSIS. <i>Schizophrenia Research</i> , 2012, 136, S34.	2.0	0
373	ALTERATIONS IN BRAIN STRUCTURE, FUNCTION AND CHEMISTRY PRIOR TO THE ONSET OF PSYCHOSIS. <i>Schizophrenia Research</i> , 2012, 136, S55.	2.0	0
374	Reduced mismatch negativity predates the onset of psychosis. <i>Schizophrenia Research</i> , 2012, 134, 42-48.	2.0	119
375	Predictive power of attenuated psychosis syndrome: Is it really low? The case of mild cognitive impairment. <i>Schizophrenia Research</i> , 2012, 135, 192-193.	2.0	9
376	Functional brain networks before the onset of psychosis: A prospective fMRI study with graph theoretical analysis. <i>NeuroImage: Clinical</i> , 2012, 1, 91-98.	2.7	40
377	Multimodal functional and structural imaging investigations in psychosis research. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 97-106.	3.2	42
378	White matter pathology â€“ an endophenotype for bipolar disorder?. <i>BMC Psychiatry</i> , 2012, 12, 138.	2.6	12

#	ARTICLE	IF	CITATIONS
379	Gray Matter Volumetric Abnormalities Associated with the Onset of Psychosis. <i>Frontiers in Psychiatry</i> , 2012, 3, 101.	2.6	33
380	Cingulate Volume Abnormalities in Emerging Psychosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 495-504.	1.9	21
381	Editorial. <i>Current Pharmaceutical Design</i> , 2012, , .	1.9	0
382	Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. <i>Journal of Psychopharmacology</i> , 2011, 25, 121-130.	4.0	406
383	Altered Medial Temporal Activation Related to Local Glutamate Levels in Subjects with Prodromal Signs of Psychosis. <i>Biological Psychiatry</i> , 2011, 69, 97-99.	1.3	59
384	Thalamic Glutamate Levels as a Predictor of Cortical Response During Executive Functioning in Subjects at High Risk for Psychosis. <i>Archives of General Psychiatry</i> , 2011, 68, 881.	12.3	114
385	Gray matters! " Mapping the transition to psychosis. <i>Schizophrenia Research</i> , 2011, 133, 63-67.	2.0	43
386	Gray matter alterations related to P300 abnormalities in subjects at high risk for psychosis: Longitudinal MRI-EEG study. <i>NeuroImage</i> , 2011, 55, 320-328.	4.2	52
387	Co-occurring mental and substance abuse disorders: A review on the potential predictors and clinical outcomes. <i>Psychiatry Research</i> , 2011, 186, 159-164.	3.3	177
388	Bupropion and Panic Disorder: Case Report and Review of the Literature. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, E47-E50.	1.8	2
389	Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. <i>Molecular Psychiatry</i> , 2011, 16, 67-75.	7.9	198
390	Altered brain function directly related to structural abnormalities in people at ultra high risk of psychosis: Longitudinal VBM-fMRI study. <i>Journal of Psychiatric Research</i> , 2011, 45, 190-198.	3.1	89
391	Affective temperamental profiles are associated with white matter hyperintensity and suicidal risk in patients with mood disorders. <i>Journal of Affective Disorders</i> , 2011, 129, 47-55.	4.1	90
392	Neuroanatomy of vulnerability to psychosis: A voxel-based meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2011, 35, 1175-1185.	6.1	319
393	Altered Prefrontal and Hippocampal Function During Verbal Encoding and Recognition in People With Prodromal Symptoms of Psychosis. <i>Schizophrenia Bulletin</i> , 2011, 37, 746-756.	4.3	71
394	Franco Basaglia (1924"1980): Three Decades (1979"2009) as a Bridge Between the Italian and Brazilian Mental Health Reform. <i>International Journal of Social Psychiatry</i> , 2011, 57, 100-103.	3.1	15
395	Prefrontal Function at Presentation Directly Related to Clinical Outcome in People at Ultrahigh Risk of Psychosis. <i>Schizophrenia Bulletin</i> , 2011, 37, 189-198.	4.3	53
396	White matter alterations related to P300 abnormalities in individuals at high risk for psychosis: an MRI"EEG study. <i>Journal of Psychiatry and Neuroscience</i> , 2011, 36, 239-248.	2.4	46

#	ARTICLE	IF	CITATIONS
397	Modulation of Auditory and Visual Processing by Delta-9-Tetrahydrocannabinol and Cannabidiol: an fMRI Study. <i>Neuropsychopharmacology</i> , 2011, 36, 1340-1348.	5.4	126
398	Social dysfunction predicts two years clinical outcome in people at ultra high risk for psychosis. <i>Journal of Psychiatric Research</i> , 2010, 44, 294-301.	3.1	92
399	From Brentano to mirror neurons: Bridging phenomenology and clinical neuroscience. <i>Psychiatry Research - Neuroimaging</i> , 2010, 183, 245-246.	1.8	3
400	Neuroimaging predictors of transition to psychosisâ€”A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2010, 34, 1207-1222.	6.1	287
401	Neural correlates of movement generation in the â€˜atâ€™risk mental stateâ€™™. <i>Acta Psychiatrica Scandinavica</i> , 2010, 122, 295-301.	4.5	17
402	Letter to the Editor: Mind the translation gap: problems in the implementation of early intervention services. <i>Psychological Medicine</i> , 2010, 40, 171-172.	4.5	3
403	Neural correlates of visuospatial working memory in the â€˜at-risk mental stateâ€™™. <i>Psychological Medicine</i> , 2010, 40, 1987-1999.	4.5	43
404	Abnormal Frontostriatal Interactions in People With Prodromal Signs of Psychosis. <i>Archives of General Psychiatry</i> , 2010, 67, 683.	12.3	235
405	Neuroimaging in cannabis use: a systematic review of the literature. <i>Psychological Medicine</i> , 2010, 40, 383-398.	4.5	189
406	Spatial working memory in individuals at high risk for psychosis: Longitudinal fMRI study. <i>Schizophrenia Research</i> , 2010, 123, 45-52.	2.0	64
407	Comment on â€œSchizophrenia, brain disease and meta-analyses: Integrating the pieces and testing Fusar-Poliâ€™s hypothesisâ€• <i>Medical Hypotheses</i> , 2010, 74, 395-396.	1.5	0
408	Effect of image analysis software on neurofunctional activation during processing of emotional human faces. <i>Journal of Clinical Neuroscience</i> , 2010, 17, 311-314.	1.5	23
409	Modulation of effective connectivity during emotional processing by δ^9 -tetrahydrocannabinol and cannabidiol. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 421.	2.1	134
410	P.3.019 A meta-analysis of neuroimaging predictors of transition to psychosis. <i>European Neuropsychopharmacology</i> , 2010, 20, S78.	0.7	0
411	Dysbindin modulates brain function during visual processing in children. <i>NeuroImage</i> , 2010, 49, 817-822.	4.2	13
412	Opposite Effects of δ^9 -Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology. <i>Neuropsychopharmacology</i> , 2010, 35, 764-774.	5.4	595
413	The effects of antipsychotics on brain structure: what have we learnt from structural imaging of schizophrenia?. <i>Psychological Medicine</i> , 2009, 39, 1781-1782.	4.5	15
414	Why Is Psychiatric Imaging Clinically Unreliable? Epistemological Perspectives in Clinical Neuroscience. <i>Psychotherapy and Psychosomatics</i> , 2009, 78, 320-321.	8.8	7

#	ARTICLE	IF	CITATIONS
415	Julius Wagner-Jauregg, 1857â€“1940. <i>American Journal of Psychiatry</i> , 2009, 166, 409-409.	7.2	4
416	Neural correlates of executive function and working memory in the â€˜at-risk mental stateâ€™™. <i>British Journal of Psychiatry</i> , 2009, 194, 25-33.	2.8	141
417	Distinct Effects of Î”9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing. <i>Archives of General Psychiatry</i> , 2009, 66, 95.	12.3	412
418	Modulation of Mediotemporal and Ventrostriatal Function in Humans by Î”9-Tetrahydrocannabinol. <i>Archives of General Psychiatry</i> , 2009, 66, 442.	12.3	226
419	Johann Cristian Reil on the 200th anniversary of the first description of the insula (1809). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 1409-1409.	1.9	9
420	Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and in firstâ€“episode psychosis. <i>Human Brain Mapping</i> , 2009, 30, 4129-4137.	3.6	189
421	Cannabis and anxiety: a critical review of the evidence. <i>Human Psychopharmacology</i> , 2009, 24, 515-523.	1.5	398
422	Maurice Merleauâ€“Ponty and the â€œEmbodied Subjectivityâ€•(1908â€“61). <i>Medical Anthropology Quarterly</i> , 2009, 23, 91-93.	1.4	8
423	Lifestyles and Cardiovascular Risk in Individuals With Functional Psychoses. <i>Perspectives in Psychiatric Care</i> , 2009, 45, 87-99.	1.9	20
424	Duration of untreated prodromal symptoms and 12-month functional outcome of individuals at risk of psychosis. <i>British Journal of Psychiatry</i> , 2009, 194, 181-182.	2.8	52
425	Neurophysiological response to emotional faces with increasing intensity of fear: A skin conductance response study. <i>Journal of Clinical Neuroscience</i> , 2009, 16, 981-982.	1.5	9
426	Can neuroimaging prove that schizophrenia is a brain disease? A radical hypothesis. <i>Medical Hypotheses</i> , 2009, 73, 855-856.	1.5	1
427	Laterality effect on emotional faces processing: ALE meta-analysis of evidence. <i>Neuroscience Letters</i> , 2009, 452, 262-267.	2.1	185
428	Genetic Vulnerability to Affective Psychopathology in Childhood: A Combined Voxel-Based Morphometry and Functional Magnetic Resonance Imaging Study. <i>Biological Psychiatry</i> , 2009, 66, 231-237.	1.3	29
429	Superior temporal gray and white matter changes in schizophrenia or antipsychotic related effects?. <i>Schizophrenia Research</i> , 2009, 113, 109-110.	2.0	14
430	Abnormal thalamic glutamate and liability to psychosis: State or trait marker?. <i>Schizophrenia Research</i> , 2009, 115, 94-95.	2.0	7
431	Distinct Effects of D9-tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing. <i>European Psychiatry</i> , 2009, 24, .	0.2	4
432	Opposite Neural Effects of the Main Psychoactive Ingredients of Cannabis- Neural Basis for Potential Therapeutic Effects of Cannabidiol. <i>European Psychiatry</i> , 2009, 24, .	0.2	0

#	ARTICLE	IF	CITATIONS
433	P.3.02 Opposite neural effects of the main psychoactive ingredients of cannabis – implications for therapeutics. <i>European Neuropsychopharmacology</i> , 2009, 19, S63-S64.	0.7	1
434	The Effects of Antipsychotics on the Brain: What Have We Learnt from Structural Imaging of Schizophrenia? – A Systematic Review. <i>Current Pharmaceutical Design</i> , 2009, 15, 2535-2549.	1.9	191
435	Imaging the Neural Effects of Cannabinoids: Current Status and Future Opportunities for Psychopharmacology. <i>Current Pharmaceutical Design</i> , 2009, 15, 2603-2614.	1.9	50
436	Editorial [Hot Topic: Perspectives in Psychopharmacological Neuroimaging (Executive Editor: Paolo) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.9	0
437	Multimodal functional imaging investigation before and after the onset of psychosis. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 579.	2.1	5
438	Pseudohallucinations Versus True Hallucinations in Prodromal Psychosis. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1056-1057.	2.2	3
439	Functional atlas of emotional faces processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging studies. <i>Journal of Psychiatry and Neuroscience</i> , 2009, 34, 418-32.	2.4	959
440	Insular pathology in the at-risk mental state. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 254-255.	3.2	4
441	NEURAL CORRELATES OF VERBAL EPISODIC MEMORY IN THE AT RISK MENTAL STATE. <i>Schizophrenia Research</i> , 2008, 102, 29-30.	2.0	0
442	DOPAMINERGIC MODULATION OF PREFRONTAL FUNCTIONING IN SUBJECTS AT CLINICAL RISK FOR PSYCHOSIS: A COMBINED PET-fMRI STUDY. <i>Schizophrenia Research</i> , 2008, 102, 30.	2.0	1
443	Neural Basis of δ^9 -Tetrahydrocannabinol and Cannabidiol: Effects During Response Inhibition. <i>Biological Psychiatry</i> , 2008, 64, 966-973.	1.3	179
444	Albert Hofmann, the Father of LSD (1906–2008). <i>Neuropsychobiology</i> , 2008, 58, 53-54.	1.9	3
445	Second Life virtual world: A heaven for autistic people?. <i>Medical Hypotheses</i> , 2008, 71, 980-981.	1.5	14
446	Successful antidepressive treatment with mirtazapine following lung transplantation. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1745-1746.	4.8	1
447	Functional neuroimaging in schizophrenia: diagnosis and drug discovery. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 91-98.	8.7	138
448	P.3.21 Delta-9-tetrahydrocannabinol modulates activity in parahippocampal cortex and ventral striatum during memory processing. <i>European Neuropsychopharmacology</i> , 2008, 18, s80.	0.7	0
449	P.1.e.020 Effects of cannabis ingredients in the temporal cortex – neural basis for potential antipsychotic effect of cannabidiol. <i>European Neuropsychopharmacology</i> , 2008, 18, S270-S271.	0.7	0
450	Determinants of Quality of Life in Marfan Syndrome. <i>Psychosomatics</i> , 2008, 49, 243-248.	2.5	53

#	ARTICLE	IF	CITATIONS
451	Anterior cingulate pathology in the prodromal stage of schizophrenia. <i>NeuroImage</i> , 2008, 39, 553-554.	4.2	34
452	Neuroimaging studies of the early stages of psychosis: A critical review. <i>European Psychiatry</i> , 2008, 23, 237-244.	0.2	44
453	Paul Eugen Bleuler and the Birth of Schizophrenia (1908). <i>American Journal of Psychiatry</i> , 2008, 165, 1407-1407.	7.2	43
454	Brain Damage. <i>Academic Medicine</i> , 2008, 83, 742.	1.6	3
455	Franco Basaglia, 1924â€“1980. <i>American Journal of Psychiatry</i> , 2008, 165, 968-968.	7.2	9
456	Egas Moniz (1875â€“1955), the father of psychosurgery. <i>British Journal of Psychiatry</i> , 2008, 193, 50-50.	2.8	10
457	Differential Diagnosis Between the Early Onset of Schizophrenia and Bipolar Disorder: <i>Potential Role of Neuroimaging</i> . <i>CNS Spectrums</i> , 2008, 13, 363-364.	1.2	2
458	â€˜Trumanâ€™ signs and vulnerability to psychosis. <i>British Journal of Psychiatry</i> , 2008, 193, 168-168.	2.8	20
459	Albert Hofmann. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 484.	1.4	1
460	Heterogeneity in the Assessment of the At-Risk Mental State for Psychosis. <i>Psychiatric Services</i> , 2008, 59, 813-813.	2.0	10
461	Roger Keith â€œSydâ€•Barrett (1946â€“2006). <i>American Journal of Psychiatry</i> , 2007, 164, 1028-1028.	7.2	3
462	Commentary. <i>Academic Medicine</i> , 2007, 82, 1109.	1.6	2
463	Anxiety and depression after lung transplantation: Mirtazapine as a first-choice agent?. <i>Journal of Psychosomatic Research</i> , 2007, 62, 101.	2.6	2
464	Memantine as a neuroprotective agent in early phases of psychosis. <i>Medical Hypotheses</i> , 2007, 68, 459-460.	1.5	2
465	Can acute tryptophan depletion modulate brain function in absence of behavioural effects?. <i>Medical Hypotheses</i> , 2007, 68, 722.	1.5	4
466	Can neuroimaging reduce social stigma in schizophrenia?. <i>Medical Hypotheses</i> , 2007, 69, 457.	1.5	2
467	Uncovering the neural correlates of the ketogenic diet: The contribution of functional neuroimaging. <i>Medical Hypotheses</i> , 2007, 69, 705-706.	1.5	2
468	Potential therapeutical effects of cannabidiol in children with pharmaco-resistant epilepsy. <i>Medical Hypotheses</i> , 2007, 68, 920-921.	1.5	21

#	ARTICLE	IF	CITATIONS
469	Linking autism, regression and Landau-Kleffner syndrome: Integrative role of nerve growth factor. <i>Medical Hypotheses</i> , 2007, 68, 1178-1179.	1.5	5
470	Imaging Genomics – An integrative approach to understand the biological susceptibility for schizophrenia. <i>Medical Hypotheses</i> , 2007, 68, 1426.	1.5	3
471	Marfan syndrome and liability to psychosis. <i>Medical Hypotheses</i> , 2007, 68, 1173-1174.	1.5	6
472	Quetiapine as a first-choice agent in subjects at high-risk to psychosis?. <i>Medical Hypotheses</i> , 2007, 69, 230.	1.5	3
473	Targeting the effects of omega-3 and omega-6 fatty acid supplementation on schizophrenic spectrum disorders: Role of neuroimaging. <i>Medical Hypotheses</i> , 2007, 69, 466-467.	1.5	2
474	Integrating the negative psychotic symptoms in the high risk criteria for the prediction of psychosis. <i>Medical Hypotheses</i> , 2007, 69, 959-960.	1.5	22
475	Is a DNA sequence variation of the gene protocadherin Y a possible explanation for the sixfold higher risk to develop schizophrenia in moroccan males?. <i>Medical Hypotheses</i> , 2007, 69, 694.	1.5	1
476	Getting Old With a New Heart: Impact of Age on Depression and Quality of Life in Long-term Heart Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 544-548.	0.6	17
477	Effects of acute antipsychotic treatment on brain activation in first episode psychosis: An fMRI study. <i>European Neuropsychopharmacology</i> , 2007, 17, 492-500.	0.7	48
478	Pooling of data in psychiatric neuroimaging: A bridge towards clinical neuroimaging?. <i>European Psychiatry</i> , 2007, 22, 265-265.	0.2	2
479	Can antidepressants prevent psychosis?. <i>Lancet, The</i> , 2007, 370, 1746-1748.	13.7	84
480	Paired associate learning in subjects at risk for psychosis: fMRI study. <i>European Psychiatry</i> , 2007, 22, S314.	0.2	0
481	Neurofunctional correlates of vulnerability to psychosis: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2007, 31, 465-484.	6.1	276
482	Love and brain: From mereological fallacy to –folk–neuroimaging. <i>Psychiatry Research - Neuroimaging</i> , 2007, 154, 285-286.	1.8	3
483	Modulation of neural response to happy and sad faces by acute tryptophan depletion. <i>Psychopharmacology</i> , 2007, 193, 31-44.	3.1	37
484	Depression After Lung Transplantation: Causes and Treatment. <i>Lung</i> , 2007, 185, 55-65.	3.3	32
485	Acute Tryptophan Depletion and Suicidality. <i>Journal of Psychophysiology</i> , 2007, 21, 72-73.	0.7	0
486	P.3.d.013 Correlation between acute atypical antipsychotic treatment and cognitive functioning in first episode psychosis. <i>European Neuropsychopharmacology</i> , 2006, 16, S436.	0.7	0

#	ARTICLE	IF	CITATIONS
487	Anti-depressive Therapies After Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 785-793.	0.6	35
488	Conceptual issues in psychiatric neuroimaging. <i>Current Opinion in Psychiatry</i> , 2006, 19, 608-612.	6.3	28
489	Effect of acute tryptophan depletion on pre-frontal engagement. <i>Psychopharmacology</i> , 2006, 187, 486-497.	3.1	38
490	Neuroimaging and electrophysiological studies of the effects of acute tryptophan depletion: a systematic review of the literature. <i>Psychopharmacology</i> , 2006, 188, 131-143.	3.1	52
491	Socioeconomic provisions for specialist training in Italy and the UK: integrating the differences. <i>Postgraduate Medical Journal</i> , 2006, 82, 810-812.	1.8	0
492	Depression and Quality of Life in Patients Living 10 to 18 Years Beyond Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 2269-2278.	0.6	52
493	Ten Years of "Extended" Life: Quality of Life Among Heart Transplantation Survivors. <i>Transplantation</i> , 2004, 78, 257-263.	1.0	74